HKPD
What one share of Cellyan Biotechnology Co. holds
Wholesale – Drugs, Proprietaries and Druggists' Sundries
China. While over 90% of the products we deal with are OTC pharmaceutical products on average, our portfolio also includes non-pharmaceutical items such as health supplements.
Cellyan Biotechnology Co.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $0.82 |
|---|---|
| Profit | −$0.07 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.05 |
| Cash and investments | $0.01 |
| Debt | $0.05 |
| Book value | $0.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2026 | $0.82 | −$0.07 | $0.00 | −$0.05 | — | $0.59 |